Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:ABT
  • CUSIP: 00282410
  • Web:
  • Market Cap: $77.58 billion
  • Outstanding Shares: 1,735,272,000
Average Prices:
  • 50 Day Moving Avg: $43.77
  • 200 Day Moving Avg: $42.22
  • 52 Week Range: $36.76 - $45.84
  • Trailing P/E Ratio: 46.52
  • Foreward P/E Ratio: 16.20
  • P/E Growth: 1.59
Sales & Book Value:
  • Annual Revenue: $22.3 billion
  • Price / Sales: 3.48
  • Book Value: $18.07 per share
  • Price / Book: 2.47
  • Annual Dividend: $1.06
  • Dividend Yield: 2.4%
  • EBIDTA: $4.77 billion
  • Net Margins: 6.71%
  • Return on Equity: 15.74%
  • Return on Assets: 8.27%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.25%
  • Average Volume: 6.55 million shs.
  • Beta: 0.97
  • Short Ratio: 2.01

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, February 17th. Stockholders of record on Friday, April 14th will be paid a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date is Tuesday, April 11th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings data on Wednesday, April, 19th. The company reported $0.48 EPS for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.05. The firm had revenue of $6.34 billion for the quarter, compared to the consensus estimate of $6.16 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business's revenue was up 29.7% on a year-over-year basis. During the same period last year, the company earned $0.41 earnings per share. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY17 earnings guidance on Wednesday, April, 19th. The company provided earnings per share (EPS) guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.45.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 analysts have issued twelve-month price objectives for Abbott Laboratories' shares. Their predictions range from $42.00 to $55.00. On average, they expect Abbott Laboratories' share price to reach $48.64 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (5/26/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:

  • Miles D. White, Chairman of the Board, Chief Executive Officer
  • Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
  • Michael T. Rousseau, President - Cardiovascular and Neuromodulation
  • Hubert L. Allen, Executive Vice President, General Counsel, Secretary
  • Stephen R. Fussell, Executive Vice President - Human Resources
  • Brian J. Blaser, Executive Vice President - Diagnostics Products
  • John M. Capek Ph.D., Executive Vice President - Ventures
  • Robert B. Ford, Executive Vice President - Medical Devices
  • Heather L. Mason, Executive Vice President - Nutritional Products
  • Roger Bird, Senior Vice President - U.S. Nutrition

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.64%), Massachusetts Financial Services Co. MA (0.00%), Wellington Management Group LLP (0.00%) and Bank of New York Mellon Corp (1.96%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Pzena Investment Management LLC, FMR LLC, SG Americas Securities LLC, Macquarie Group Ltd., APG Asset Management N.V., Camber Capital Management LLC and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, State Street Corp, Boston Partners, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of Abbott Laboratories stock can currently be purchased for approximately $44.71.

MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  483 (Vote Outperform)
Underperform Votes:  337 (Vote Underperform)
Total Votes:  820
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $48.64 (8.78% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Goldman Sachs Group IncInitiated CoverageNeutral -> Neutral$45.00LowView Rating Details
5/15/2017Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
5/12/2017Jefferies Group LLCReiterated RatingBuy$50.00 -> $51.00LowView Rating Details
4/22/2017Cowen and CompanyReiterated RatingOutperform$48.00MediumView Rating Details
4/20/2017Barclays PLCBoost Price TargetOverweight -> Overweight$50.00 -> $52.00LowView Rating Details
4/19/2017Morgan StanleyReiterated RatingEqual Weight$42.00LowView Rating Details
4/18/2017Stifel NicolausReiterated RatingBuy$49.00MediumView Rating Details
3/14/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$48.00MediumView Rating Details
9/19/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/30/2015 forward)


Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20172$0.60$0.61$0.61
Q3 20172$0.64$0.68$0.66
Q4 20172$0.72$0.73$0.73
Q1 20181$0.56$0.56$0.56
Q2 20181$0.71$0.71$0.71
Q3 20181$0.74$0.74$0.74
Q4 20181$0.84$0.84$0.84
(Data provided by Zacks Investment Research)


Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Most Recent Dividend:5/15/2017
Annual Dividend:$1.06
Dividend Yield:2.37%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:113.98% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.41% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
DateHeadline logoGlobal Markets May Drive Established Pharmaceuticals Growth - May 29 at 3:17 PM logoAbbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 29, 2017 - May 29 at 3:17 PM logoEmerging Markets Drive Abbott’s Nutritional Business Growth - May 26 at 3:15 PM logoAbbott Continues to Expand Its Diagnostics Portfolio in 2017 - May 26 at 3:15 PM logoTop Analyst Reports for Visa, GE, GlaxoSmithKline & Others - May 26 at 3:15 PM logoAbbott Laboratories (ABT) Rating Increased to Buy at Zacks Investment Research - May 26 at 10:59 AM logoHow Will Abbott Laboratories Benefit from Its Alere Acquisition? - May 25 at 8:32 PM logoThe Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon - May 25 at 3:30 PM logoIs Medical Technology Driving the US Healthcare Industry? - May 25 at 3:30 PM logoFDA: Controller for heart pump recalled over deaths - May 24 at 6:29 PM logoAbbott Laboratories (ABT) Lowered to "Hold" at Zacks Investment Research - May 24 at 9:04 AM logoEdward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna - May 24 at 5:17 AM logoAbbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? - Nasdaq - May 22 at 3:15 PM logoAbbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? - May 22 at 3:15 PM logoAbbott Laboratories (ABT) Downgraded by TheStreet - May 21 at 10:34 PM logoNew Div On The Block Quarterly Earnings Round-Up: Part 2 - May 21 at 1:19 AM logoVTV, ABT, MDLZ, AET: Large Outflows Detected at ETF - May 18 at 12:36 PM logoGoldman Sachs Group Inc Initiates Coverage on Abbott Laboratories (ABT) - May 16 at 8:56 PM logoFormer Angels, Orioles star convicted of insider trading - May 16 at 8:18 PM logoGoldman Starts Abbott Laboratories at 'Neutral' - - May 16 at 3:17 PM logoGoldman Sachs Starts Abbott Labs (ABT) at Neutral - - May 16 at 3:17 PM logoGoldman Starts Abbott Laboratories at 'Neutral' - May 16 at 3:17 PM logoAbbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research - May 16 at 10:57 AM logoAbbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Analysts - May 15 at 9:42 AM logoRetired baseball player DeCinces found guilty of insider trading - May 12 at 8:30 PM logoAbbott Laboratories' (ABT) Buy Rating Reiterated at Jefferies Group LLC - May 12 at 7:46 AM logoIYY, AGN, ABT, MDLZ: Large Outflows Detected at ETF - May 11 at 12:03 AM logoAbbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ - May 9 at 9:31 AM logoBuying A Very Safe Dividend - May 8 at 8:17 PM logoAbbott Laboratories – Value Analysis (NYSE:ABT) : May 8, 2017 - May 8 at 8:17 PM logoAbbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes - May 8 at 11:29 AM logoAbbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor - May 8 at 11:29 AM logo Analysts Expect Abbott Laboratories (ABT) Will Post Quarterly Sales of $6.63 Billion - May 7 at 7:54 AM logoAbbott's Interesting Quarter - Seeking Alpha - May 6 at 3:27 PM logoAbbott Laboratories (ABT) Expected to Post Earnings of $0.60 Per Share - May 5 at 8:24 PM logoAbbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 5, 2017 - May 5 at 3:17 PM logoAnalysis Of AbbVie's Pipeline: What's Left Of Abbott's Biopharma Growth Opportunities? - May 4 at 3:16 PM logoAbbott Laboratories (ABT) Given Daily News Sentiment Score of 0.09 - May 2 at 7:48 AM logoAlere, set to be acquired by Abbott, dealt setback in Medicare case - May 1 at 3:17 PM logoAbbott Laboratories (ABT) Given Daily Media Impact Rating of 0.18 - April 29 at 8:42 AM logoJoseph J. Manning Sells 4,200 Shares of Abbott Laboratories (ABT) Stock - April 29 at 1:09 AM logoAbbott Laboratories (ABT) Insider Sells $245,392.00 in Stock - April 29 at 1:09 AM logoAbbott launches nutrition drinks for surgery patients - Seeking Alpha - April 26 at 3:25 PM logoAbbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery - April 26 at 3:25 PM logoAbbott Laboratories (ABT) Getting Somewhat Negative Media Coverage, Analysis Shows - April 26 at 9:18 AM logoGlobal Market For Medical Implants To Hit Nearly $27 Billion In 5 Years - April 26 at 5:54 AM logoAbbott's First Quarter: Medical Device Segment Grows Over 100% - April 25 at 3:17 PM logoCramer's lightning round: Nobody ever made money betting against this CEO - April 25 at 6:37 AM logoAbbott Laboratories: Constantly Adapting For Enduring Success - April 24 at 11:18 AM logoQ3 2017 EPS Estimates for Abbott Laboratories Cut by Leerink Swann (ABT) - April 24 at 8:44 AM



Abbott Laboratories (ABT) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by Staff